Letter to the Editor

Cindhya Sithiravel, Ragnhild Røysland, Bashir Alaour, Marit Sverresdotter Sylte, Janniche Torsvik, Heidi Strand, Michael Marber, Torbjørn Omland and Kristin Moberg Aakre*

Biological variation, reference change values and index of individuality of GDF-15

https://doi.org/10.1515/cclm-2021-0769
Received July 6, 2021; accepted September 21, 2021;
published online October 14, 2021

Keywords: analytical performance goal; biomarker; clinical interpretation; diagnosis; monitoring; prognosis.

To the Editor,

GDF-15 is an upcoming and promising prognostic inflammatory biomarker found to be elevated in a wide range of diseases, including cancer and cardiovascular diseases [1–3]. Knowledge about the biological variation of GDF-15 is useful for suggesting analytical performance specifications. Furthermore, it aids in determining the number and frequency of samplings needed, as components with large biological variation may require several measurements to establish an individuals’ homeostatic set point, which is necessary to confirm a diagnosis or assess prognosis.

Reference change values (RCV) help determine whether the changes in results on serial testing within the same individual is clinically significant or can be explained by analytical or physiological variation. The index of individuality (II) allows us to distinguish between analyses where the population-based reference intervals or absolute cut-offs are relevant (index >1.4) and analyses where the subject-based reference intervals (i.e., delta changes) are more appropriate (index <0.6) [4, 5]. Previous studies have shown conflicting results concerning the biological variation, RCV and II of GDF-15 [6, 7].

We carried out a multicenter study at Haukeland University Hospital, Akershus University Hospital in Norway, King’s College London and Guy’s and St Thomas’ Hospital, United Kingdom. The study design was planned according to the EFLM checklist for biological variation studies (BIVAC) [8], and is described earlier [9]. Thirty healthy volunteers were recruited, 16 were women and two were daily smokers. Age range was 21–64 years (median 36 years). Participants had no evident disease, and no previous history of chronic illness. Screening tests including glucose, eGFR, high-sensitivity troponin and NT-proBNP were performed at baseline. Healthy-status was defined biochemically as:

- Non fasting glucose ≤7.8 mmol/L
- eGFR(CKD-EPIcreat) >60 mL/min/1.73 m²
- cTnT <99th percentile for the assay (<14 ng/L)
- NT-proBNP <the local reference limit

Venous blood sampling was performed weekly, on the same weekday ±1 day, for 10 consecutive weeks, and separated serum was stored at −80 °C until analysis. GDF-15 was analyzed in duplicates, with the same reagent and calibrator lot at Akershus University Hospital on the Cobas e801 (Roche Diagnostics, Switzerland). The limit of detection (LOD) and limit of quantification (LOQ) was 400 ng/L (CV_A of ±20%), and the measuring range was 400–20,000 ng/L. The CV_A was 0.47% at concentration 1,372–7,458 ng/L.

In total 17/30 (57%) individuals had ≥4 duplicate measurements above the LOD, and were eligible for further analysis. Analytical outliers were removed according to Burnett test, and outliers in mean values according to
Reeds criteria [9]. The serial values for each individual were checked for linear trend using linear regression; subjects with significant trend (p-value of 0.01) were removed. Cochrane’s and Bartlett’s test were used to test homogeneity of analytical and within-subject variances, outliers were removed until homogeneity was achieved. Shapiro–Wilk test was used to test normality of the residuals. Thirteen subjects were included in the final analysis. Median concentrations were calculated for the total cohort, gender- and age-specific subgroups, differences in individual medians between age and gender groups were tested using Mann Whitney U test. Biological variation, RCV and II were done on ln transformed data and CVln is the adjoining re-transformed CV.

The distribution of the data was skewed (non-parametric) and calculations of $\sigma_A, \sigma_I, \sigma_G$ were done on ln transformed data, using nested balanced ANOVA. The $\sigma$ was thereafter retransformed into analytical variation (CVa), within-subject variation (CVi), and between-subject variation (CVg) using:

$$CV_{ln} = \sqrt{(\exp(\sigma^2) - 1) \times 100}$$

in which $\sigma$ is the estimated standard deviation for the ln-transformed data and $CV_{ln}$ is the adjoining re-transformed CV.

The RCV values (with 95% confidence intervals) were calculated according to Fokkema et al. [10]:

$$RCV_{pos} = \left[ \exp\left(1.96 \times 2^{\frac{1}{2}} \times (\sigma_A^2 + \sigma_I^2)^{\frac{1}{2}} \right) - 1 \right] \times 100$$

$$RCV_{neg} = \left[ \exp\left(-1.96 \times 2^{\frac{1}{2}} \times (\sigma_A^2 + \sigma_I^2)^{\frac{1}{2}} \right) - 1 \right] \times 100$$

in which $\sigma_A$ is the analytic standard deviation and $\sigma_I$ is the within-person standard deviation of the logarithmic data.

The II was calculated using the retransformed data as follows:

$$II = \sqrt{CV_A^2 + CV_I^2} / CV_G$$

![Figure 1: Median and range of 295 concentrations (ng/L) in the 30 participants.](image)

To visualize our data immeasurable values (values <LOD) are shown as 400 ng/L. These values are not included in the calculations of biological variation.
Desirable analytical performance goals was calculated as [5]:

$$CV_A < \frac{1}{2} CV_I$$

$$Bias < \frac{1}{4} \sqrt{CV_I^2 + CV_G^2}$$

Median GDF-15 concentration for all participants (13 individuals) was 515 (25 and 75 percentile, 463–652) ng/L. No difference in GDF-15 values between men (n=6) and women (n=7) was observed (median, 468 vs. 545 ng/L, for men vs. women, respectively; p-value for difference 0.36). Median concentration was higher in participants ≥45 years (n=8) compared to those <45 years (n=5): 719 vs. 470 ng/L, respectively; p-value for difference 0.03. The smokers were excluded due to measured results below LOD, hence the GDF-15 concentrations (Quantikine®; R&D Systems, Inc., Minneapolis, MN, USA). For healthy subjects, they reported a higher CV (18.9%) and CV_A (15.2%), compared to our findings.

Based on our data we suggest the following analytical performance specifications; 3.8% as desirable CV_A, and 6.2% as desirable analytical bias. In agreement with our and Krintus’ [6] results and the precision data reported by Roche, routine laboratories should be able to fulfill these performance specifications, utilizing the Roche Elecsys immunoassay.

The strength of our study is the standardized protocol and firm data analysis. The limitation is the relative low number of included subjects since many participants were excluded due to measured results below LOD, hence the variability in subjects with GDF-15 below LOD is unknown.

Table 1: Estimates of biological variation, reference change values (RCV) and index of individuality (II) for GDF-15, median concentration (25 and 75 percentile) are calculated after exclusion of outliers.

|                          | Total cohort | Age <45 years | Age ≥45 years |
|--------------------------|-------------|---------------|---------------|
| Number of samples (participants) | 120 (13)    | 52 (8)        | 49 (5)        |
| Median concentrations (25–75 percentile), ng/L | 515 (463–652) | 470 (447–529) | 719 (579–810) |
| CV_A, mean (95% CI), %  | 1.8 (1.6–2.1) | 1.9 (1.6–2.4) | 1.6 (1.4–2.0) |
| CV_I, mean (95% CI), %   | 7.6 (6.6–9.0) | 7.4 (6.1–9.4) | 7.9 (6.5–10.0) |
| CV_G, mean (95% CI), %   | 23.6 (16.1–38.6) | 6.5 (3.5–14.6) | 19.2 (11.1–58.9) |
| RCVpos, mean (95% CI), %  | 24.3 (20.9–28.9) | 23.6 (19.3–30.5) | 24.9 (20.3–32.3) |
| RCVneg, mean (95% CI), %  | –19.5 (–22.4 to –17.3) | –19.1 (–23.4 to –16.1) | –20.0 (–24.4 to –16.9) |
| II, mean (95% CI)        | 0.35 (0.20–0.51) | 1.15 (0.40–2.03) | 0.43 (0.11–0.79) |

Exclusion of samples or participants

| Least than four samplings showed measurable results | 14 participants (ID 3, 4, 5, 7, 9) | 13 participants (ID 3, 4, 5, 7, 16, 17, 19, 21, 24, 26, 27, 29, 30) | One participant (ID 9) |
| Analytical outliers | One sample result (ID 11) | One participant (ID 8) | One sample result (ID 11) |
| Exclusion due to a significant 10 week trend (p-value <0.01) | One participant (ID 11) | One participant (ID 23) | One participant (ID 11) |
| Exclusion due to Dix-Reed criterion | One participant (ID 11) | One participant (ID 23) | One participant (ID 11) |
| Exclusion due to within-subject non-homogeneity according to Bartlett or Cochrans test | None | None | None |
| Exclusion due to analytical non-homogeneity according to Bartlett or Cochrans test | None | None | None |

The lower part of the table shows number and reasons for sample or participant exclusions. RCV, reference change values; II, index of individuality.
The age groups were chosen arbitrary, and small group size resulted in larger uncertainty for the age-specific estimates, and these need confirmation in other studies. Also, our study only included healthy subjects, so the biological variation data are not applicable for interpreting clinical relevant changes in patients with chronic disease. However, Meijers et al. measured CVr and CVc in healthy subjects and heart failure patients, and did not find discrepancy between the two groups. Applicability in diseased populations still needs confirmation in future studies.

Our results confirm earlier findings of biological variation, RCV and II of GDF-15. The low biological variation and RCV indicate a biomarker useful for prognostication in individual subjects. The low II signals that subject-based reference intervals could be more appropriate than population based reference intervals or using an absolute cut offs (i.e., 1,800 ng/L) as suggested for prognostication today [3]. Finally, the biological variation is sufficiently large compared to the analytical variation, indicating that desirable analytical performance of GDF-15 measurements should be achievable in routine laboratories.

**Research funding:** The study was supported by a grant from the Dept. of Medical Biochemistry and Pharmacology, Haukeland University Hospital, a grant from the University of Oslo and grants from the Medical Research Council (London, UK) (G1000737), Guy's and St Thomas' Charity (London, UK; R060701, R100404), British Heart Foundation (Birmingham, London; TG/15/1/31518, FS/18/78/33902), and the UK Department of Health through the National Institute for Health Research Biomedical Research Centre award to Guy's & St Thomas' National Health Service Foundation Trust.

**Author contributions:** All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Competing interests:** Kristin M. Aakre has served on advisory boards for Roche Diagnostics and received personal fees from Siemens Healthineers. Torbjørn Omland has served on advisory boards for Abbott Diagnostics, Roche Diagnostics and Bayer and has received research support from Abbott Diagnostics, Novartis, Roche Diagnostics, Singulex and SomaLogic via Akershus University Hospital, and speaker’s or consulting honoraria from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers and CardiNor. Dr. Omland is also listed as an inventor on a patent application entitled: “GDF-15 for predicting the disease severity of a patient with COVID-19” and on the granted patent applications *Grainin proteins as markers of heart disease.* PCT/GB0818650.4 SgII as a prognostic marker in conditions which require critical care. CT/GBO919901.9. Cindhya Sithiravel, Ragnhild Røysland, Bashir Alaour, Marit S. Sylte, Janniche Torsvik, Heidi Strand, Michael Marber report no conflict of interest.

**Informed consent:** Informed consent was obtained from all individuals included in this study.

**Ethical approval:** This study was carried out according to the principles of the Declaration of Helsinki. The protocol was approved by the respective regional ethics committee at each centre: South Central – Berkshire Research Ethics Committee (London), and the Regional Committee for Medical and Health Research Ethics in Bergen (Bergen and Oslo).

**References**

1. Baek SJ, Eling T. Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases. Pharmacol Ther 2019;198:46–58.
2. Adela DR, Banerjee S. Review article GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. Jo Diabetic Res 2015;2015. https://doi.org/10.1155/2015/490842.
3. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 2017;63:140–51.
4. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409–37.
5. Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics, 5th ed. USA: Saunders; 2011.
6. Krintus M, Braga F, Kozinski M, Borille S, Kubica J, Sypniewska G, et al. A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. Clin Chem Lab Med 2019;57:1035–43.
7. Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail 2017;19:357–65.
8. Aarsand AK, Reraas T, Fernandez-Calle P, Ricos C, Diaz-Garzon J, Jonker N, et al. The biological variation data critical appraisal checklist: a standard for evaluating studies on biological variation. Clin Chem 2018;64:501–14.
9. Alaour B, Omland T, Torsvik J, Kaier TE, Sylte MS, Strand H, et al. Biological variation of cardiac myosin-binding protein C in healthy individuals. Accepted for publication in Clin Chem Lab Med 2021. https://doi.org/10.1515/cclm-2021-0306.
10. Fokkema MR, Herrmann Z, Muskiet FA, Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006;52:1602–3.